CompletedPhase 3

Aldara for the Treatment of Large and/or Multiple sBCC

France111 participantsStarted 2003-05

Plain-language summary

BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * One or more sBCC on torso, neck or face * Total surface area \<= 40 sq cm Exclusion Criteria: * Pregnancy or women who are breastfeeding * Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors * Metatypical, adnexal, or sclerodermiform carcinomas * Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the region of the current lesion * Known HIV positive serology * Skin tumor that is already or highly likely to become metastatic * Presence of a clinically significant anomaly or illness (immunological, cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine, gastrointestinal, collagenous) * Previous organ transplant history

What they're measuring

Clinical clearance of sBCC

Timeframe: 12 or 16 weeks after treatment

Trial details

NCT IDNCT00189280

SponsorMEDA Pharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-10

View on ClinicalTrials.gov More Carcinoma, Basal Cell trials